Article

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
The Lancet (Impact Factor: 45.22). 07/2008; 371(9631):2192-200. DOI: 10.1016/S0140-6736(08)60954-X
Source: PubMed

ABSTRACT Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours.
126 detoxified heroin-dependent patients, from an outpatient research clinic and detoxification programme in Malaysia, were randomly assigned by a computer-generated randomisation sequence to 24 weeks of manual-guided drug counselling and maintenance with naltrexone (n=43), buprenorphine (n=44), or placebo (n=39). Medications were administered on a double-blind and double-dummy basis. Primary outcomes, assessed by urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours over 6 months. The study was terminated after 22 months of enrolment because buprenorphine was shown to have greater efficacy in an interim safety analysis. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00383045.
We observed consistent, linear contrasts in days to first heroin use (p=0.0009), days to heroin relapse (p=0.009), and maximum consecutive days abstinent (p=0.0007), with all results best for buprenorphine and worst for placebo. Buprenorphine was associated with greater time to first heroin use than were naltrexone (hazard ratio 1.87 [95% CI 1.21-2.88]) or placebo (2.02 [1.29-3.16]). With buprenorphine, we also recorded significantly greater time to heroin relapse (2.17 [1.38-3.42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43-76] vs 24 [13-35]; p=0.003); however, for these outcomes, differences between buprenorphine and naltrexone were not significant. Differences between naltrexone and placebo were not significant for any outcomes. HIV risk behaviours were significantly reduced from baseline across all three treatments (p=0.003), but the reductions did not differ significantly between the three groups.
Our findings lend support to the widespread dissemination of maintenance treatment with buprenorphine as an effective public-health approach to reduce problems associated with heroin dependence.

Download full-text

Full-text

Available from: Marek C Chawarski, Aug 27, 2014
0 Followers
 · 
107 Views
  • Source
    • "Effects of the three treatment arms on primary and secondary outcomes were reported previously (Schottenfeld, Chawarski, and Mazlan 2008). All ICERs for primary outcomes – days in treatment, days in treatment without heroin use, days in treatment without heroin relapse, and maximum consecutive days abstinent --were below $50 per additional day (Figure 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To aid public health policymaking, we studied the cost-effectiveness of buprenorphine, naltrexone, and placebo interventions for heroin dependence in Malaysia. We estimated the cost-effectiveness ratios of three treatments for heroin dependence. We used a microcosting methodology to determine fixed, variable, and societal costs of each intervention. Cost data were collected from investigators, staff, and project records on the number and type of resources used and unit costs; societal costs for participants' time were estimated using Malaysia's minimum wage. Costs were estimated from a provider and societal perspective and reported in 2004 US dollars. Muar, Malaysia. 126 patients enrolled in a randomized, double-blind, placebo-controlled clinical trial in Malaysia (2003-2005) receiving counseling and buprenorphine, naltrexone, or placebo for treatment of heroin dependence. Primary outcome measures included days in treatment, maximum consecutive days of heroin abstinence, days to first heroin use, and days to heroin relapse. Secondary outcome measures included treatment retention, injection drug use, illicit opiate use, AIDS Risk Inventory total score, and drug risk and sex risk subscores. Buprenorphine was more effective and more costly than naltrexone for all primary and most secondary outcomes. Incremental cost-effectiveness ratios were below $50 for primary outcomes, mostly below $350 for secondary outcomes. Naltrexone was dominated by placebo for all secondary outcomes at almost all endpoints. Incremental treatment costs were driven mainly by medication costs, especially the price of buprenorphine. Buprenorphine appears to be a cost-effective alternative to naltrexone that might enhance economic productivity and reduce drug use over a longer term.
    PLoS ONE 12/2012; 7(12):e50673. DOI:10.1371/journal.pone.0050673 · 3.53 Impact Factor
  • Source
    • "The short version of AIDS Risk Inventory, assessing drug-related and sexual risk behaviors associated with HIV transmission (Chawarski et al., 1998), was administered at baseline and 3 and 6 months after study enrollment. A Mandarin Chinese version of this assessment, translated by native Mandarin Chinese-speaking co-investigators in previous studies in Malaysia and China and then back translated and checked for accuracy and equivalence, has been used in several previous studies (Chawarski et al., 2008, Schottenfeld at al., 2008). Illicit drug use was measured by at least monthly urine testing using rapid/instant urine tests for opiates (morphine). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This pilot clinical trial evaluated whether the efficacy of methadone maintenance treatment (MMT) provided with limited psychosocial services is improved by the addition of manual-guided behavioral drug and HIV risk reduction counseling (BDRC). Heroin dependent individuals (n=37) enrolling in two MMT clinics in Wuhan, China, received standard MMT services, consisting of daily medication at the clinics and infrequent additional services on demand, and were randomly assigned to MMT only (n=17) or MMT with weekly individual BDRC (n=20) for 3 months. Participants were followed for six months from the time of enrollment (3 months active counseling phase and 3 months follow-up while treated with standard MMT). Primary outcome measures included reductions of HIV risk behaviors and illicit opiate use and treatment retention. Participants were 81% male; mean (SD) age 36.7 (7.2) years; there were no significant baseline differences between the two groups. Participants in MMT+BDRC achieved both greater reductions of HIV risk behaviors (p<0.01), as indicated by the scores on a short version of the AIDS Risk Inventory, and of illicit opiate use, as indicated by the proportions of opiate negative test results during the active phase of the study and the follow-up (p<0.001). 83.3% in the MMT+BDRC group and 76.2% in the standard MMT group were still actively participating in MMT at 6 months. Manual-guided behavioral drug and HIV risk reduction counseling is feasible to deliver by the trained MMT nursing personnel and appears to be a promising approach for improving the efficacy of standard MMT services in China.
    Drug and alcohol dependence 06/2011; 115(3):237-9. DOI:10.1016/j.drugalcdep.2010.09.024 · 3.28 Impact Factor
  • Source
    • "However, within the past 5 years, the number and proportion of cases using B-MAT have increased (Magura et al., 2009), with multiple studies demonstrating its safety and effectiveness (Kaur et al., 2008; Magura et al., 2007) and the role that therapy duration plays in treatment outcomes (Fiellin et al., 2008). The relationship between treatment outcomes and adherence with medication has been documented within many diseases, including addiction (Cramer et al., 2003; Schottenfeld et al., 2008). Results largely indicate that patients with chronic diseases who are adherent with their medication regimen tend to have better outcomes (Dolor et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Opioid-dependent (OD) patients seeking treatment have multiple treatment options including abstinence-based and medication replacement therapies. A recent and growing addition to medication replacement therapy is buprenorphine medication-assisted treatment (B-MAT), which may be provided by certified physicians practicing in private offices. Research on OD treatment is often performed on samples of patients recruited from specialty treatment facilities, which may not generalize to B-MAT patients. Thus, B-MAT as a treatment approach has been understudied. The present research describes (a) new methods developed to facilitate sample recruitment and survey data collection from a national B-MAT patient sample and (b) a telephonic support program designed for new B-MAT patients. Results indicate that by using appropriate tools, it is feasible to conduct a clinical study of B-MAT patients, recruited at the point of service, and that telephonic patient support was an acceptable treatment adjunct.
    Journal of substance abuse treatment 12/2010; 39(4):307-17. DOI:10.1016/j.jsat.2010.07.003 · 2.90 Impact Factor
Show more